Verastem (VSTM) Competitors $5.97 -0.15 (-2.45%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$6.03 +0.06 (+1.01%) As of 06/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. MNKD, INVA, DVAX, NVAX, OPK, GERN, RGLS, ZBIO, MYGN, and RIGLShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Verastem vs. Its Competitors MannKind Innoviva Dynavax Technologies Novavax OPKO Health Geron Regulus Therapeutics Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Verastem (NASDAQ:VSTM) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Which has preferable earnings & valuation, VSTM or MNKD? MannKind has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$10M32.80-$87.37M-$3.20-1.87MannKind$297.60M3.96-$11.94M$0.1038.80 Does the MarketBeat Community believe in VSTM or MNKD? Verastem received 30 more outperform votes than MannKind when rated by MarketBeat users. Likewise, 65.36% of users gave Verastem an outperform vote while only 60.35% of users gave MannKind an outperform vote. CompanyUnderperformOutperformVerastemOutperform Votes61965.36% Underperform Votes32834.64% MannKindOutperform Votes58960.35% Underperform Votes38739.65% Which has more risk and volatility, VSTM or MNKD? Verastem has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Do analysts rate VSTM or MNKD? Verastem presently has a consensus price target of $13.63, indicating a potential upside of 128.22%. MannKind has a consensus price target of $10.00, indicating a potential upside of 157.73%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is VSTM or MNKD more profitable? MannKind has a net margin of 8.07% compared to Verastem's net margin of 0.00%. MannKind's return on equity of -17.74% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -332.73% -73.97% MannKind 8.07%-17.74%8.68% Does the media favor VSTM or MNKD? In the previous week, MannKind had 15 more articles in the media than Verastem. MarketBeat recorded 17 mentions for MannKind and 2 mentions for Verastem. Verastem's average media sentiment score of 0.93 beat MannKind's score of 0.56 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals & insiders believe in VSTM or MNKD? 88.4% of Verastem shares are owned by institutional investors. Comparatively, 49.5% of MannKind shares are owned by institutional investors. 2.1% of Verastem shares are owned by company insiders. Comparatively, 2.7% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryMannKind beats Verastem on 13 of the 19 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$328.05M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-1.878.7827.1720.06Price / Sales32.80255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book2.636.557.064.70Net Income-$87.37M$143.93M$3.23B$247.88M7 Day Performance-3.40%3.97%2.89%2.66%1 Month Performance-18.11%11.32%9.06%6.40%1 Year Performance67.70%4.20%31.40%14.07% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem3.217 of 5 stars$5.97-2.5%$13.63+128.2%+72.0%$328.05M$10M-1.8750Positive NewsMNKDMannKind3.0781 of 5 stars$4.29+3.4%$10.00+133.1%-16.6%$1.30B$297.60M61.29400Trending NewsInsider TradeAnalyst RevisionINVAInnoviva4.1431 of 5 stars$20.14+2.9%$55.00+173.1%+34.4%$1.26B$369.84M29.19100News CoverageHigh Trading VolumeDVAXDynavax Technologies4.1705 of 5 stars$9.84+0.5%$24.00+143.9%-15.8%$1.18B$294.62M54.67350NVAXNovavax3.8954 of 5 stars$7.07-3.7%$19.00+168.7%-57.6%$1.15B$1.21B-3.131,990Trending NewsOPKOPKO Health4.4952 of 5 stars$1.38+1.5%$2.75+99.3%+2.3%$1.09B$689.41M-7.264,200News CoverageGERNGeron3.1565 of 5 stars$1.43-5.9%$5.06+254.0%-69.7%$910.79M$116.29M-4.4770RGLSRegulus Therapeutics1.7194 of 5 stars$7.94+0.1%$8.50+7.1%+237.5%$549.72MN/A-7.4230Positive NewsZBIOZenas Biopharma1.3302 of 5 stars$10.06+5.7%$36.67+264.5%N/A$420.85M$15M-2.83N/ATrending NewsHigh Trading VolumeMYGNMyriad Genetics4.1021 of 5 stars$4.46+6.4%$14.79+231.5%-76.9%$411.11M$831.30M-3.432,600High Trading VolumeRIGLRigel Pharmaceuticals3.2834 of 5 stars$20.15+4.9%$36.40+80.6%+107.7%$360.12M$203.08M143.94160Positive NewsAnalyst Revision Related Companies and Tools Related Companies MannKind Alternatives Innoviva Alternatives Dynavax Technologies Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Zenas Biopharma Alternatives Myriad Genetics Alternatives Rigel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
